This tricyclic antidepressant has quite varying indications when comparing the Dutch and British formularies, and will be one of the focal points in the area of antidepressants in particular, and psychotropics in general.


My comparison will continue in the next few days with anti-depressants. This is a fairly large category, which will probably take me about a week to get through. Again, the comparison is not (at this stage) comparing the clinical efficacy of any compound to another, but a formulary comparison.

Not marketing

I have come across several instances (lurasidone being a case in point) where a manufacturer has registered one or more strengths of their entity, without applying for the strength to be marketed. An enquiry with Takeda, which markets Latuda (lurasidone), as to why 18.5 mg is not available in NL remains open.